12:00 AM
Oct 27, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Lenalidomide: Phase III started

Last quarter, Celgene began a Phase III (SWOG S0777) trial in 440 patients to evaluate oral Revlimid plus low-dose dexamethasone with or without

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >